Webinar
Webinar: InVitria + Evonik
Article · Published 2026-09-16 · 1 min read
From Cell Banking to Cell Therapy: The Role of Recombinant Albumin in Cryopreservation

Why Attend This Webinar?
- Understand how animal component-free rHSA can reduce variability and support more defined cell therapy manufacturing workflows.
- See how rHSA performs in iPSC, T cell, and MSC cryopreservation models, including post-thaw outcomes beyond viability.
- Learn how recombinant albumin compares with plasma-derived albumin in purity, consistency, and supply security.
- Get practical guidance on evaluating rHSA for GMP workflows, including formulation fit, qualification, comparability, and closed-system integration.

Featured Products
The session features Evonik’s CreaCyte® rHSA for biomanufacturing, powered by Optibumin® 25, InVitria’s ready-to-use 25% liquid recombinant albumin designed for biomanufacturing and closed-system workflows.
Meet the Speakers

Cléa Michel
Global Director Product Management, Biopharma Solutions | Evonik Health Care
Michel leads Evonik’s portfolio of ingredients and technologies for biopharmaceutical manufacturing, from transient protein expression and upstream media optimization to downstream purification and drug product formulation. She draws on a background in biochemistry and biotechnology to help biopharma companies improve process performance.

Dr. Mark Stathos
Director, Cell Biology | InVitria
Dr. Stathos leads InVitria’s Cell Biology lab, producing application notes and publications on how InVitria products perform in industrially relevant applications such as cell and gene therapy manufacturing. He has more than a decade of hands-on cell culture experience and holds a PhD in Bioengineering from Georgia Tech.

Jake Hanks
Director, Business Development | InVitria
Hanks supports InVitria’s key accounts, building strategic partnerships that guide customers through evaluation, qualification, regulatory approval, and scale-up. He holds a BS and an MBA from the University of Tulsa.
Reserve Your Spot
Registration is hosted by Evonik.
CreaCyte® is a registered trademark of Evonik. Optibumin® is a registered trademark of InVitria.
Products Mentioned
-
Exbumin®
Approved excipient recombinant human serum albumin, supplied as a lyophilized powder for therapeutic formulation, vaccine stabilization, and viral vector processing.
-
Cellastim® S
Cell culture recombinant albumin to enhance proliferation in serum free and chemically defined cell culture. Lyophilized.
-
Optibumin® 25
Approved excipient 25% recombinant human serum albumin, supplied in bottles and closed-system friendly bags for processing, formulation, cryopreservation, and advanced biomanufacturing.
More resources
Keep reading.
Accelerating Vaccine Development Through Use of Blood-Free Components
Talk to a Scientist
See how rHSA performs in your media.
Send us your cell line and formulation and we will help you design a side-by-side evaluation against your current albumin.